Rafael Esteban

Q: What Schools Are Affiliated With Rafael Esteban

Rafael Esteban is affiliated with the following schools: University of California, Berkeley, Autonomous University of Barcelona, Stanford University, University of Barcelona

Rafael Esteban's AcademicInfluence.com Rankings

Rafael Esteban

Computer Science

#6088

World Rank

#6419

Historical Rank

Machine Learning

#1859

World Rank

#1884

Historical Rank

Artificial Intelligence

#2107

World Rank

#2143

Historical Rank

Database

#3202

World Rank

#3338

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Rafael Esteban's Degrees

PhD Computer Science Stanford University
Masters Computer Science University of California, Berkeley

Similar Degrees You Can Earn

Why Is Rafael Esteban Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Rafael Esteban's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Boceprevir for previously treated chronic HCV genotype 1 infection. (2011) (1711)
EASL Clinical Practice Guidelines: management of chronic hepatitis B. (2009) (1471)
Epidemiology of hepatitis C virus infection. (1993) (1192)
Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution (1992) (984)
HEPATITIS C VIRUS ANTIBODIES AMONG RISK GROUPS IN SPAIN (1989) (907)
Sofosbuvir and ribavirin in HCV genotypes 2 and 3. (2014) (824)
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. (2010) (739)
Thrombocytopenia associated with chronic liver disease. (2008) (483)
Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. (2004) (426)
Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis. (1990) (392)
Transmission of hepatitis C virus by a cardiac surgeon. (1996) (385)
European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. (1999) (349)
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. (2016) (303)
Cardiac alterations in cirrhosis: reversibility after liver transplantation. (2005) (289)
Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis (1991) (263)
High-Throughput Real-Time Reverse Transcription-PCR Quantitation of Hepatitis C Virus RNA (1999) (248)
The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference * (2011) (245)
Role of hepatitis B, C, and D viruses in dual and triple infection: Influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference (2001) (239)
The development of low-grade cerebral edema in cirrhosis is supported by the evolution of (1)H-magnetic resonance abnormalities after liver transplantation. (2001) (235)
The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B (2017) (214)
Quality of life and cognitive function in hepatitis C at different stages of liver disease. (2003) (207)
Hepatitis B virus infection: Precore mutants and its relation to viral genotypes and core mutations (1995) (206)
Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. (2005) (152)
Effects of Branched-Chain Amino Acids Supplementation in Patients With Cirrhosis and a Previous Episode of Hepatic Encephalopathy: A Randomized Study (2011) (148)
Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. (2015) (147)
Predicting early mortality after acute variceal hemorrhage based on classification and regression tree analysis. (2009) (144)
Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. (1992) (134)
Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. (2010) (131)
Quality of life in cirrhosis is related to potentially treatable factors (2010) (130)
Detection of early portal hypertension with routine data and liver stiffness in patients with asymptomatic liver disease: a prospective study. (2014) (130)
Clinical outcome of acute and chronic hepatitis delta over time: a long‐term follow‐up study (2011) (127)
Effectiveness of Combined Pharmacologic and Ligation Therapy in High-Risk Patients With Acute Esophageal Variceal Bleeding (2011) (120)
Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis (1999) (118)
Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. (2005) (114)
Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa‐2b plus ribavirin (2002) (114)
Sporadic cases of acute autochthonous hepatitis E in Spain. (2004) (107)
Management of hepatitis C virus genotype 4: recommendations of an international expert panel. (2011) (104)
Community-Based Seroepidemiological Survey of Hepatitis E Virus Infection in Catalonia, Spain (2006) (98)
Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. (2013) (98)
Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. (2014) (97)
ROLE OF DOPPLER ECHOCARDIOGRAPHY IN THE ASSESSMENT OF PORTOPULMONARY HYPERTENSION IN LIVER TRANSPLANTATION CANDIDATES1 (2001) (97)
Dynamic behavior of hepatitis C virus quasispecies in patients undergoing orthotopic liver transplantation (1994) (96)
Development of a clinical hepatic encephalopathy staging scale (2007) (89)
Interferon‐α in acute posttransfusion hepatitis C:. A randomized, controlled trial (1992) (86)
Sofosbuvir/Velpatasvir for 12 Weeks in Hepatitis C Virus-Infected Patients with End-Stage Renal Disease Undergoing Dialysis. (2019) (86)
Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. (2005) (85)
Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. (2009) (85)
Neuropsychological abnormalities in cirrhosis include learning impairment. (2006) (84)
Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus–infected patients with congenital coagulation disorders (2001) (84)
Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. (2007) (83)
Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. (2007) (82)
Randomized trial of peginterferon alfa‐2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response (2010) (80)
Liver involvement in multiple myeloma (1985) (78)
High-Resolution Hepatitis C Virus Subtyping Using NS5B Deep Sequencing and Phylogeny, an Alternative to Current Methods (2014) (78)
Nucleotide and Amino Acid Complexity of Hepatitis C Virus Quasispecies in Serum and Liver (2000) (77)
A cost‐effectiveness analysis of peginterferon alfa‐2b plus ribavirin for the treatment of naive patients with chronic hepatitis C (2003) (76)
Validity of the Spanish version of the Chronic Liver Disease Questionnaire (CLDQ) as a standard outcome for quality of life assessment (2006) (76)
Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. (2018) (75)
Quantitative detection of hepatitis B virus DNA in serum by a new rapid real‐time fluorescence PCR assay (2001) (75)
Increased tumour necrosis factor α production in mesenteric lymph nodes of cirrhotic patients with ascites (2003) (74)
Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. (2008) (73)
Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study (2017) (73)
Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine? (2002) (72)
Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C. (2000) (72)
Management of direct-acting antiviral agent failures. (2015) (72)
The State of Hepatitis B and C in the Mediterranean and Balkan Countries: Report from a Summit Conference (2013) (71)
Hypercholesterolemia in long-term survivors of liver transplantation: a comparison between cyclosporine and FK 506. (1998) (69)
Extending combination therapy with peginterferon alfa‐2b plus ribavirin for genotype 1 chronic hepatitis C late responders: A report of 9 cases (2003) (69)
Structure of replicating hepatitis C virus (HCV) quasispecies in the liver may not be reflected by analysis of circulating HCV virions (1997) (69)
Long interval between HCV infection and development of hepatocellular carcinoma. (2008) (69)
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. (2018) (68)
Peginterferon alpha‐2b plus ribavirin vs interferon alpha‐2b plus ribavirin for chronic hepatitis C in HIV‐coinfected patients (2007) (68)
Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. (2019) (67)
Hepatitis B virus genome variability and disease progression: the impact of pre-core mutants and HBV genotypes. (2005) (64)
Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. (2013) (63)
Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. (2020) (63)
Effectiveness and Safety of Sofosbuvir/Velpatasvir/ Voxilaprevir in Patients with Chronic Hepatitis C Previously Treated with DAAs. (2019) (59)
HIV, HEV and cirrhosis: evidence of a possible link from eastern Spain (2012) (59)
Tyrosine kinase inhibition ameliorates the hyperdynamic state and decreases nitric oxide production in cirrhotic rats with portal hypertension and ascites. (1997) (59)
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. (2020) (57)
Ultra-Deep Pyrosequencing Detects Conserved Genomic Sites and Quantifies Linkage of Drug-Resistant Amino Acid Changes in the Hepatitis B Virus Genome (2012) (56)
Two years of lamivudine therapy in anti‐HBe‐positive patients with chronic hepatitis B (2001) (56)
Mutations in the basic core promoter region of hepatitis B virus. Relationship with precore variants and HBV genotypes in a Spanish population of HBV carriers. (2004) (55)
Hemodynamic response–guided therapy for prevention of variceal rebleeding: An uncontrolled pilot study (2006) (55)
Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin (2012) (54)
Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma (2017) (54)
A comparative study of ultra-deep pyrosequencing and cloning to quantitatively analyze the viral quasispecies using hepatitis B virus infection as a model. (2013) (51)
Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants. (1999) (51)
Hepatitis E infection in acute sporadic hepatitis in Spain (1993) (50)
Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment‐naive patients (2007) (50)
Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals (2017) (49)
Ultra-deep pyrosequencing analysis of the hepatitis B virus preCore region and main catalytic motif of the viral polymerase in the same viral genome (2011) (48)
O8 SUCCESSFUL RETREATMENT WITH SOFOSBUVIR-CONTAINING REGIMENS FOR HCV GENOTYPE 2 OR 3 INFECTED PATIENTS WHO FAILED PRIOR SOFOSBUVIR PLUS RIBAVIRIN THERAPY (2014) (48)
Management of direct antiviral agent failures (2016) (47)
Effectiveness and safety of sofosbuvir‐based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real‐life cohort (2017) (47)
Hemoperitoneum as a First Manifestation of Hepatocellular Carcinoma in Western Patients with Liver Cirrhosis (2001) (47)
Usefulness of dried blood samples for quantification and molecular characterization of HBV‐DNA (2004) (47)
484 PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN (2011) (46)
Hepatitis E virus infection in acute hepatitis in Spain. (1995) (46)
Genetic alterations in the S gene of hepatitis B virus in patients with acute hepatitis B, chronic hepatitis B and hepatitis B liver cirrhosis before and after liver transplantation. (1999) (46)
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. (2012) (45)
Serum hepatitis B core-related antigen is more accurate than hepatitis B surface antigen to identify inactive carriers, regardless of hepatitis B virus genotype. (2017) (45)
Liver transplantation in HIV-HCV coinfected patients: a case-control study. (2007) (45)
Superiority of Interferon-Free Regimens for Chronic Hepatitis C (2017) (44)
Specific Cleavage of Hepatitis C Virus RNA Genome by Human RNase P* (2002) (43)
Analysis of hepatitis B genotype changes in chronic hepatitis B infection: Influence of antiviral therapy. (2008) (43)
Serological diagnosis of acute delta hepatitis (1986) (43)
Cirrhosis, Liver Transplantation and HIV Infection Are Risk Factors Associated with Hepatitis E Virus Infection (2014) (43)
Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation (2002) (42)
Oral glutamine challenge and magnetic resonance spectroscopy in three patients with congenital portosystemic shunts. (2004) (42)
Effect of Bottlenecking on Evolution of the Nonstructural Protein 3 Gene of Hepatitis C Virus during Sexually Transmitted Acute Resolving Infection (2005) (41)
Adrenomedullin, a Vasodilator Peptide Implicated in Hemodynamic Alterations of Liver Cirrhosis Relationship to Nitric Oxide (1999) (41)
Hepatitis D virus RNA in acute delta infection: Serological profile and correlation with other markers of hepatitis D virus infection (1988) (41)
The value of quantiative detection of HBV-DNA amplified by PCR in the study of hepatitis B infection (1996) (41)
Efficacy of screening donors for antibodies to the hepatitis C virus to prevent transfusion‐associated hepatitis: Final report of a prospective trial (1995) (39)
Treatment with Interferon plus Ribavirin in anti-HIV Negative Patients with Congenital Coagulation Disorders and Chronic Hepatitis C (2000) (39)
Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab. (2009) (39)
Prevalence of Hepatitis E Virus Infection in Children in the Northeast of Spain (2008) (37)
Hepatitis B virus genotypes and G1896A precore mutation in 486 Spanish patients with acute and chronic HBV infection (2006) (37)
Hepatitis b virus replication in acute hepatitis B, acute hepatitis B virus‐hepatitis delta virus coinfection and acute hepatitis delta superinfection (1987) (37)
Alpha-interferon for acute hepatitis C in liver transplant patients. (1995) (36)
Hepatitis B vaccination in liver transplant candidates (2001) (36)
Interleukin 28B polymorphisms are the only common genetic variants associated with low‐density lipoprotein cholesterol (LDL‐C) in genotype‐1 chronic hepatitis C and determine the association between LDL‐C and treatment response (2012) (35)
Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine. (1998) (35)
Antiviral Activity of ANA773, an Oral Inducer of Endogenous Interferons that Acts Via TLR7, in Chronic Hepatitis C Patients (2011) (35)
Are recipients of solid organ transplantation a high‐risk population for hepatitis E virus infection? (2010) (35)
The value of quantitative detection of HBV-DNA amplified by PCR in the study of hepatitis B infection. (1996) (34)
Down-regulation of genes related to the adrenergic system may contribute to splanchnic vasodilation in rat portal hypertension. (2008) (33)
Quantitative hepatitis B virus DNA testing for the early prediction of the maintenance of response during lamivudine therapy in patients with chronic hepatitis B. (2001) (33)
Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain (2008) (33)
Determination of hepatitis delta virus RNA by polymerase chain reaction in acute and chronic delta infection (1995) (33)
Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir? (2012) (33)
Chronic delta hepatitis: Is the prognosis worse when associated with hepatitis C virus and human immunodeficiency virus infections? (1996) (33)
Long‐term follow‐up of hemodynamic responders to pharmacological therapy after variceal bleeding (2012) (32)
Immunoprophylaxis of perinatal transmission of the hepatitis B virus: Efficacy of hepatitis B immune globulin and hepatitis B vaccine in a low‐prevalence area (1986) (32)
Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients (2007) (32)
Immune‐related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors (2020) (31)
Long‐term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia (2019) (31)
Demonstration of hepatitis D virus RNA in patients with chronic hepatitis. (1988) (31)
Transmission of hepatitis B virus by transplantation of livers from donors positive for antibody to hepatitis B core antigen. (1999) (31)
Early Antiviral Treatment of Hepatitis C Virus Recurrence after Liver Transplantation in HIV-Infected Patients (2006) (30)
Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials. (2014) (30)
Long‐term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B (2018) (30)
Longitudinal Evaluation of the Structure of Replicating and Circulating Hepatitis C Virus Quasispecies in Nonprogressive Chronic Hepatitis C Patients (2001) (29)
Role of immunosuppression in the development of quinolone‐resistant Escherichia coli spontaneous bacterial peritonitis and in the mortality of E. coli spontaneous bacterial peritonitis (2003) (29)
Chronic delta hepatitis: Detection of hepatitis delta virus antigen in serum by immunoblot and correlation with other markers of delta viral replication (1989) (29)
Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis (2014) (29)
Hepatitis C virus Core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alpha-2b plus ribavirin. (2004) (28)
Development of sofosbuvir for the treatment of hepatitis C virus infection (2015) (28)
Clinical Application of Estimating Hepatitis B Virus Quasispecies Complexity by Massive Sequencing: Correlation between Natural Evolution and On-Treatment Evolution (2014) (28)
Early detection of nonresponse to interferon plus ribavirin combination treatment of chronic hepatitis C (2002) (28)
Hepatitis C virus infection in renal transplant recipients: epidemiology, clinical impact, serological confirmation and viral replication. (1995) (28)
Interferon-alpha in acute posttransfusion hepatitis C: a randomized, controlled trial. (1992) (28)
Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. (2019) (28)
141 EXTENDED TREATMENT DURATION IN CHRONIC HEPATITIS C GENOTYPE 1-INFECTED SLOW RESPONDERS: FINAL RESULTS OF THE SUCCESS STUDY (2009) (27)
Genome Wide-Association Study Identifies Il28B Polymorphism to Be Associated with Baseline Alt and Hepatic Necro-Inflammatory Activity in Chronic Hepatitis C Patients Enrolled in the Ideal Study (2010) (27)
Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus (2018) (26)
Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study. (2011) (25)
Sexual Transmission of Hepatitis C Virus From a Patient With Chronic Disease to His Sex Partner After Removal of an Intrauterine Device (2003) (25)
Etiology of acute sporadic hepatitis in Spain: the role of hepatitis C and E viruses. (1994) (24)
[Consensus document of the Spanish Association for the Study of the Liver on the treatment of hepatitis B infection (2012)]. (2012) (24)
CLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus (2010) (24)
Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial. (2009) (24)
Atrophy of mesenteric sympathetic innervation may contribute to splanchnic vasodilation in rat portal hypertension (2010) (23)
New therapeutic perspectives in HBV: when to stop NAs (2014) (23)
[Study of HLA-II antigens in chronic hepatitis C and B and in acute hepatitis B]. (1997) (22)
Il28B Genotype Is Not Associated with Advanced Hepatic Fibrosis in Chronic Hepatitis C Patients Enrolled in the Ideal Study (2010) (22)
High doses of β‐blockers and alcohol abstinence improve long‐term rebleeding and mortality in cirrhotic patients after an acute variceal bleeding (2010) (22)
Evaluation of RNA and E2 antibodies in prospectively followed recipients of hepatitis G virus‐infected blood (1999) (22)
Cost‐effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg‐negative chronic hepatitis B (2006) (21)
Anti-HD IgM as a marker of chronic delta infection. (1987) (21)
Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection. (2017) (20)
Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa‐2b/ribavirin (2013) (20)
Recurrent hepatitis C virus infection after liver transplantation: immunohistochemical assessment of the viral antigen. (1998) (20)
Hepatic resection or orthotopic liver transplant in cirrhotic patients with small hepatocellular carcinoma. (1995) (20)
7 BOCEPREVIR IN ADDITION TO STANDARD OF CARE ENHANCED SVR IN HEPATITIS C VIRUS (HCV) GENOTYPE-1 WITH ADVANCED FIBROSIS/CIRRHOSIS: SUBGROUP ANALYSIS OF SPRINT-2 AND RESPOND-2 STUDIES (2011) (19)
Listeria monocytogenes-associated acute hepatitis in a liver transplant recipient. (2008) (19)
Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes (2018) (19)
Molecular epidemiology and putative origin of hepatitis C virus in random volunteers from Argentina. (2013) (19)
Entecavir, FTC, L-FMAU, LdT and others. (2003) (19)
Profiles of GBV‐C/hepatitis G virus markers in patients coinfected with hepatitis C virus (1999) (19)
Prevalence of hepatitis G virus in healthy children in liver disease, and human immunodeficiency virus-1 infection: response to interferon. (2000) (18)
Structural analysis of hepatitis C RNA genome using DNA microarrays. (2004) (18)
Hepatitis delta genotypes in chronic delta infection in the northeast of Spain (Catalonia) (1998) (18)
[Cost effectiveness of the treatment of chronic hepatitis C with interferon-alpha]. (1998) (18)
Healthcare value of implementing hepatitis C screening in the adult general population in Spain (2018) (18)
Evidence of an Exponential Decay Pattern of the Hepatitis Delta Virus Evolution Rate and Fluctuations in Quasispecies Complexity in Long-Term Studies of Chronic Delta Infection (2016) (18)
Tenofovir discontinuation after long-term viral suppression in HBeAg negative chronic hepatitis B. Can HBsAg levels be useful? (2015) (17)
Management of chronic hepatitis B: an overview. (2002) (17)
Hepatitis B virus infection in alcoholic cirrhosis (1981) (17)
Does pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIg and nucleos(t)ide analogues? (2011) (17)
Hepatitis C virus markers in patients with acute post-transfusion hepatitis treated with interferon alfa-2b. (1993) (17)
Unexpected long‐lasting anti‐HEV IgM positivity: Is HEV antigen a better serological marker for hepatitis E infection diagnosis? (2020) (17)
Clinical and serological outcome of acute delta infection. (1987) (17)
Quasispecies dynamics in main core epitopes of hepatitis B virus by ultra-deep-pyrosequencing. (2012) (16)
Clinical significance of two forms of IgM antibody to hepatitis delta virus (1991) (16)
Nosocomial transmission of hepatitis C virus during contrast-enhanced computed tomography scanning (2008) (16)
Utility of early testing for HCV viremia as predictive factor of sustained response during interferon or interferon plus ribavirin treatment. (2000) (16)
Influence of human immunodeficiency virus infection on cell-mediated immunity in chronic D hepatitis. (1991) (16)
Hepatitis C virus genotype 3: a genotype that is not ‘easy-to-treat’ (2015) (16)
Early pleural effusion in histiocytosis X. (1979) (16)
Hepatitis B‐associated membranous glomerulonephritis treated with adenine arabinoside monophosphate (1986) (15)
Therapy for hepatitis C genotype 3: moving forward (2015) (15)
Brucellar hepatic abscess. (1991) (15)
HBV Core Region Variability: Effect of Antiviral Treatments on Main Epitopic Regions (2011) (15)
Risk of hepatitis B in infancy and childhood. (1995) (15)
Epidemiology of delta infection in Spain (1988) (15)
Hepatitis B virus and hepatitis D virus replication in HBsAg‐positive fulminant hepatitis (1990) (14)
Profiles and clinical management of hepatitis C patients in Spain: disHCovery study. (2015) (14)
Optimal management of chronic hepatitis B patients receiving nucleos(t)ide analogues (2020) (14)
[Pleural effusion in rheumatoid arthritis]. (1976) (14)
Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients. (2012) (14)
Somatostatin plus isosorbide 5-mononitrate versus somatostatin in the control of acute gastro-oesophageal variceal bleeding: a double blind, randomised, placebo controlled clinical trial (2000) (14)
Alcohol consumption and risk of infection after a variceal bleeding in low‐risk patients (2016) (14)
Prevalence of circulating antibodies against the hepatitis C virus among different risk groups in Spain (1989) (14)
Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). (2020) (13)
Blockage of the afferent sensitive pathway prevents sympathetic atrophy and hemodynamic alterations in rat portal hypertension (2012) (13)
Boceprevir in Addition to Standard of Care Enhanced SVR in Hepatitis C Virus (HCV) Genotype-1 With Advanced Fibrosis/Cirrhosis: Subgroup Analysis of SPRINT-2 and RESPOND-2 Studies (2011) (13)
Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats (2012) (13)
Ribavirin therapy in chronic delta hepatitis. (1993) (13)
Cost‐effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis (2017) (13)
Assessment of a Novel Automatic Real-Time PCR Assay on the Cobas 4800 Analyzer as a Screening Platform for Hepatitis C Virus Genotyping in Clinical Practice: Comparison with Massive Sequencing (2016) (13)
Comparative analysis of serological markers of chronic delta infection: HDV-RNA, serum HDAg and anti-HD IgM. (1994) (13)
CASE REPORT: Usefulness of Magnetic Resonance Spectroscopy for Diagnosis of Hepatic Encephalopathy in a Patient with Relapsing Confusional Syndrome (2001) (12)
P1075 PAGE-B: RISK SCORE FOR HEPATOCELLULAR CARCINOMA (HCC) DEVELOPMENT IN CAUCASIAN CHRONIC HEPATITIS B (CHB) PATIENTS RECEIVING ENTECAVIR (ETV) OR TENOFOVIR (TDF) (2014) (12)
Financial impact of two different ways of evaluating early virological response to peginterferon-α-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1 (2012) (12)
ORAL COMMUNICATIONSOC.07.1 2-YEAR EFFECTIVENESS AND SAFETY OF TENOFOVIR IN 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE (2012) (12)
Serological profile of tissue autoantibodies during acute and chronic delta hepatitis. (1989) (12)
Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B (2021) (12)
Evaluating the cost of sustained virologic response in naïve chronic hepatitis C patients treated à la carte (2007) (12)
One‐quarter of chronic hepatitis D patients reach HDV‐RNA decline or undetectability during the natural course of the disease (2021) (12)
Relevance of a Full-Length Genomic RNA Standard and a Thermal-Shock Step for Optimal Hepatitis Delta Virus Quantification (2014) (12)
1430 SAFETY AND EFFICACY OF BOCEPREVIR/PEGINTERFERON/ RIBAVIRIN (BOC/P/R) COMBINATION THERAPY FOR CHRONIC HCV G1 PATIENTS WITH COMPENSATED CIRRHOSIS: A META-ANALYSIS OF FIVE PHASE 3 CLINICAL TRIALS (2013) (12)
High HCV subtype heterogeneity in a chronically infected general population revealed by high-resolution hepatitis C virus subtyping. (2017) (12)
De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infection (2007) (11)
Subtype mutations in the envelope 2 region including phosphorylation homology domain of Hepatitis C virus do not predict effectiveness of antiviral therapy (2004) (11)
Adefovir for Chronic Hepatitis B Treatment: Identification of Virological Markers Linked to Therapy Response (2008) (11)
Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance. (2009) (11)
Quality of life and cost-effectiveness of anti-HCV therapy in HIV-infected patients. (2006) (11)
Durability of viral response to interferon ribavirin combination in patients with chronic hepatitis C (2001) (11)
Identification of host and viral factors involved in a dissimilar resolution of a hepatitis C virus infection (2014) (11)
Severe hepatic failure after ARA-A-prednisolone for chronic type B hepatitis. (1987) (11)
Detection of hyper-conserved regions in hepatitis B virus X gene potentially useful for gene therapy (2018) (11)
Spontaneous bacterial peritonitis caused by quinolone-resistant Escherichia coli: could steroid therapy play a role? (2002) (11)
Evaluation of anti-HCV positive blood donors identified during routine screening. (1992) (11)
Interferon‐free therapies for patients with chronic hepatitis C genotype 3 infection: A systematic review (2017) (10)
Hepatitis delta genotypes in chronic delta infection in the northeast of Spain (Catalonia). (1998) (10)
Incidence and outcome of hepatitis C virus infection after liver transplantation (1994) (10)
Quantitative characterization of hepatitis delta virus genome edition by next-generation sequencing. (2018) (10)
Use of the Novel INNO-LiPA Line Probe Assay for Detection of Hepatitis B Virus Variants That Confer Resistance to Entecavir Therapy (2008) (10)
Role of Biomarkers in Guiding Cure of Viral Hepatitis B (2019) (10)
Current trends in chronic hepatitis B management: results of a questionnaire (2009) (10)
Quantification of Serum Hepatitis C Virus RNA with Daily or Standard Interferon Doses Plus Ribavirin in Nonresponder Patients with Chronic Hepatitis C (2000) (9)
Introduction: thrombocytopenia in chronic liver disease – treatment implications and novel approaches (2007) (9)
A randomized controlled trial of α-interferon in acute postransfusion C hepatitis (1990) (9)
MATERNO‐FETAL TRANSMISSION OF HEPATITIS A ANTIBODY (1980) (9)
Digoxygenin-Labelled DNA-Probe: A Rapid Non-Radioactive Method for Hepatitis B Virus DNA Detection in Serum (1991) (9)
P.1.48: EFFECTIVENESS AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN FIELD PRACTICE: A MULTICENTER EUROPEAN COHORT STUDY OF 737 PATIENTS WITH CHRONIC HEPATITIS B (2011) (9)
Analysis of hepatitis B virus preS1 variability and prevalence of the rs2296651 polymorphism in a Spanish population (2018) (9)
Evaluation of hepatitis C virus RNA RT/PCR qualitative and quantitative second generation assays. (2001) (9)
Nitric oxide may contribute to nocturnal hemodynamic changes in cirrhotic patients (2000) (8)
Hepatitis B virus quasispecies evolution after liver transplantation in patients under long‐term lamivudine prophylaxis with or without hepatitis B immune globulin (2015) (8)
Complex Genotype Mixtures Analyzed by Deep Sequencing in Two Different Regions of Hepatitis B Virus (2015) (8)
Rapid method for the detection of anti-HCV antibodies in patients with chronic hepatitis C. (2000) (8)
Non-A, Non-B, Non-C, Non-E Acute Hepatitis: Does it Really Exist? (1994) (8)
1990-2010: two decades of interferon-based therapy. (2011) (8)
Infrequent detection of hepatitis E virus RNA in pregnant women with hepatitis E virus antibodies in Spain (2010) (8)
Prevents HBV Reactivation with Tenofovir in Anti-HBC Positive Patients with Hematologic Malignancies Treated with Rituximab. Results Final Visit 18-Months (Preblin Study) (2016) (8)
Thrombotic thrombocytopenic purpura relapse induced by acute hepatitis E transmitted by cryosupernatant plasma and successfully controlled with ribavirin (2018) (8)
129 The five year follow-up of a randomized study comparing lamivudine with lamivudine+HBIG investigating the prevention of HBV recurrence after liver transplantation (2006) (8)
Twelve-Week Posttreatment Follow-Up to Predict Sustained Virologic Response for Recurrent Hepatitis C Infection in Liver Recipients (2012) (8)
Inhibition of Neuronal Apoptosis and Axonal Regression Ameliorates Sympathetic Atrophy and Hemodynamic Alterations in Portal Hypertensive Rats (2014) (8)
Hepatitis C virus genotype 4: Genotype 1's little brother (2017) (8)
558 COST-EFFECTIVENESS SIMULATION ANALYSIS OF TENOFOVIR DISOPROXIL FUMARATE (TENOFOVIR), LAMIVUDINE, ADEFOVIR DIPIVOXIL (ADEFOVIR) AND ENTECAVIR OF HBEAG NEGATIVE (-) PATIENTS WITH CHRONIC HEPATITIS-B (CHB) IN SPAIN (2008) (8)
P1119 EARLY VIRAL KINETICS DO NOT PREDICT TREATMENT OUTCOME WITH SOFOSBUVIR + RIBAVIRIN FOR 12 OR 24 WEEKS IN HCV GENOTYPE 2/3 PATIENTS IN THE VALENCE TRIAL (2014) (7)
Reflex viral load testing in dried blood spots generated by plasma separation card allows the screening and diagnosis of chronic viral hepatitis. (2020) (7)
Detection of hepatitis B precore mutants by the fluorescent linear polymerase chain reaction sequencing method. (1994) (7)
Two years lamivudine therapy in patients with chronic hepatitis B. Analysis of efficacy and emergence of HBV genomic variations (2000) (7)
An electronic alert system increases screening for hepatitis B and C and improves management of patients with haematological disorders (2020) (7)
Which is the Most Cost-Effective Combination Therapy Strategy Using Interferon α-2b plus Ribavirin for Naïve Patients with Chronic Hepatitis C? (2002) (7)
Etiologies and Features of Acute Viral Hepatitis in Spain. (2020) (7)
New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents (2010) (7)
Retreatment of interferon relapse patients with chronic hepatitis C. (1999) (7)
T-9 2-year effectiveness and safety of tenofovir in 302 NUC-naive patients with chronic hepatitis B: a multicenter European study in clinical practice (2012) (7)
Ribavirin therapy for chronic type C hepatitis (1991) (7)
731 EFFECTIVENESS AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN FIELD PRACTICE: A MULTICENTER EUROPEAN COHORT STUDY OF 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B (2011) (7)
Drug-Induced Lupus-Like Reaction and Captopril (1993) (7)
Safety and efficacy of Sofosbuvir/Velpatasvir with and without Ribavirin in genotype 3HCV-infected patients with cirrhosis (2018) (7)
High Efficacy of an 8-Week 3-Drug Regimen of Grazoprevir/MK-8408/MK-3682 in HCV Genotype 1, 2 and 3-Infected Patients: SVR24 Data from the Phase 2 C-Crest 1 and 2 Studies (2016) (7)
Treatment of chronic type D hepatitis and concomitant human immunodeficiency infection with alpha-interferon. (1992) (7)
Tenofovir monotherapy for naive patients with chronic hepatitis B: a multicenter European study in clinical practice in 302 patients followed for 30 months (2012) (7)
Adding banding ligation is effective as rescue therapy to prevent variceal rebleeding in haemodynamic non-responders to pharmacological therapy. (2012) (6)
Pyogenic liver abscess by haemophilus influenzae complicating hydatid cysts (1986) (6)
Conservation and variability of hepatitis B core at different chronic hepatitis stages (2020) (6)
Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide. (2020) (6)
ANTI-HEPATITIS-A ANTIBODY IN SPAIN (1978) (6)
Il28B Genetic Polymorphism Has Genome Wide Significant Associations with Serum Low Density Lipoprotein Levels and Hepatic Steatosis in Patients with Genotype 1 Chronic Hepatitis C (Chc) (2010) (6)
Long-Term Patient Centered Outcomes in Cirrhotic Patients with Chronic Hepatitis C After Achieving Sustained Virologic Response. (2021) (6)
Characterization of hepatitis B virus X gene quasispecies complexity in mono-infection and hepatitis delta virus superinfection (2019) (6)
525 TENOFOVIR MONOTHERAPY FOR NAÏVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE IN 302 PATIENTS FOLLOWED FOR 30 MONTHS (2012) (6)
P0641 : Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the impact of hepatocellular carcinoma (HCC) (2015) (6)
New hepatitis C virus genotype 1 subtype naturally harbouring resistance-associated mutations to NS5A inhibitors. (2018) (6)
T-12 Tenofovir suppressed viral suppression in most field practice, treatment-naïve patients with CHB followed for 3 years in a multicenter European study (2013) (6)
[Hepatocellular carcinoma: clinical aspects, diagnosis, and survival in 140 cases]. (1993) (6)
WHEN SHOULD AT-RISK INFANTS BE BOOSTED WITH HEPATITIS B VACCINE? (1987) (6)
Prevalencia e incidencia de la infección por el virus de la hepatitis A en pacientes con hepatitis crónica B y C (2000) (6)
P1040 TENOFOVIR FOR THE PROPHYLAXIS OF HBV REACTIVATION IN ANTI-HBC-POSITIVE PATIENTS WITH HEMATOLOGIC MALIGNANCIES TREATED WITH RITUXIMAB: PRELIMINARY RESULTS OF A RANDOMIZED STUDY (PREBLIN STUDY) (2014) (6)
Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade. (2006) (6)
Predictors of Sustained Virologic Response Among Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin When Re-Treated With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin (2011) (5)
[Immunoprophylaxis of the vertical transmission of the hepatitis B virus. An urgent need]. (1986) (5)
Main mutations in the hepatitis B virus basic core promoter (A1762T/G1764A) before HBeAg loss are markers that identify patients who will require long‐term treatment (2010) (5)
[Distribution of the antibody against the hepatitis a an antigen (anti-VHA) among the general population (author's transl)]. (1979) (5)
The presence of anti‐hcv antibodies in the serum of patients with chronic active hepatitis and antinuclear antibodies (1990) (5)
Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade (2006) (5)
[Occurrence of antibodies against hepatitis A virus in general population. Comparative study, 1977-1985]. (1987) (5)
The role of HBV genotype in the emergence of YMDD variants in chronic hepatitis B patients treated with lamivudine (2003) (5)
Cost-effectiveness of a hepatitis B virus screening strategy to prevent reactivation in patients with hematologic neoplasms. (2017) (5)
[Quantification of hepatitis B virus HBsAg: clinical implications]. (2012) (5)
Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D (2022) (5)
Improved Attachment of Natural HCV Isolate to Daudi Cells upon Elimination of Immune Complexes and Close pH Control (2005) (5)
247 PREDICTING TREATMENT OUTCOME AMONG SLOW RESPONDERS: A RETROSPECTIVE ANALYSIS OF THE SUCCESS STUDY (2010) (5)
New real-time-PCR method to identify single point mutations in hepatitis C virus (2016) (5)
[Prevalence of markers of infection with hepatitis B, delta and HTLV-III viruses in the mentally retarded]. (1986) (5)
HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS MARKERS IN EUROPE (1979) (5)
Serological diagnosis of chronic delta infection: correlation between serological markers and hepatitis delta virus RNA in hepatic tissue. (1993) (4)
Redetection of HBV lamivudine‐resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analogues (2007) (4)
The renal effects of droxidopa are maintained in propranolol treated cirrhotic rats (2015) (4)
High-Dose Interferon-α2b Plus Ribavirin for Retreatment of Interferon-Nonresponsive Patients Infected with Genotype 1 Hepatitis C Virus (2001) (4)
Prospective efficacy trial of anti-HCV screening of donors to prevent postransfusion hepatitis (1990) (4)
Disappearance of serum hepatitis B virus DNA by polymerase chain reaction after adenine arabinoside 5'-monophosphate therapy in chronic hepatitis B. (2008) (4)
HTLV-III ANTIBODIES AND CHRISTMAS DISEASE (1986) (4)
Is there a role for interferon in acute viral hepatitis? (1993) (4)
Long-term outcome after interferon therapy in patients with chronic hepatitis C. (2007) (4)
Long term treatment with recombinat alfa2 interferon in patients with chronic delta hepatitis and human immunodeficiency antibodies (1989) (4)
[Serologic markers of hepatitis B virus]. (1985) (4)
Interferon treatment in acute posttransfusion NANB hepatitis (1990) (4)
[Assessment of the PCR-Southern blot technique for the analysis of viremia in patients with acute hepatitis A]. (2001) (4)
Rapid screening of the Cys282Tyr and His63Asp mutations in the HFE gene. (2000) (4)
466 HCV core Ag as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alfa-2B plus ribavirin (2004) (3)
Managing patients on interferon therapy (1996) (3)
IMMUNOPROPHYLAXIS FOR INFANTS BORN TO HBsAg-POSITIVE MOTHERS (1983) (3)
Detection of hepatitis delta virus RNA in human liver tissue by non-radioactive in situ hybridization. (1993) (3)
Patient experience in HCV therapy: what really matters. (2016) (3)
Serum HCV-RNA in anti-HCV-reactive donors according to RIBA-2, liver histology and infectivity (1991) (3)
Adefovir dipivoxil (2015) (3)
[Serologic markers for hepatitis B virus in a group of healthy individuals (author's transl)]. (1982) (3)
Can interferon prolong life? (2003) (3)
[Seroepidemiology of hepatitis A virus infection in medical and nursing students. The role of vaccination]. (1996) (3)
336 DETECTION OF CLINICALLY RELEVANT MINOR HCV AND HBV ANTIVIRAL-RESISTANT MUTANTS IN TREATMENT-NAIVE PATIENTS USING ULTRA-DEEP PYROSEQUENCING (2009) (3)
Study of hepatitis B virus quasispecies by ultra‐deep pyrosequencing: Resolving the nitty‐gritty (2014) (3)
Changes in different regions of hepatitis B virus gene in hepatitis B ‘e’ antigen‐negative patients with chronic hepatitis B: the effect of long‐term lamivudine therapy (2005) (3)
What to do when standard therapy fails. (2000) (3)
Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B (2021) (3)
Anti-HBc impacts on the risk of hepatitis B reactivation but not on survival of solid-organ transplant recipients (2020) (3)
Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020) (2020) (3)
[Study of hepatitis B virus replication and infection by other hepatitis viruses in patients with chronic hepatitis B virus infection]. (2002) (3)
Chronic delta infection in a patient without detectable HBsAg in serum (1988) (3)
Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction? (2012) (3)
Is the universal population Hepatitis C virus screening a cost-effective strategy? A systematic review of the economic evidence (2020) (3)
Prolonged inhibition of hepatitis B virus replication with vidarabine monophosphate in chronic active type B hepatitis. (2008) (2)
[Therapy of chronic hepatitis B]. (2008) (2)
Sclerosing Cholangitis Related to IgG4: Not Always a Curable Entity. (2019) (2)
Preparing the patient for success: treat or wait? (2013) (2)
HCV reinfection in liver transplanted recipients assessed by HCV-AG expression in liver cells (1995) (2)
Hemoglobin Decline During Lead-in Phase as an Early Predictor of Anemia After the Addition of Boceprevir: A Retrospective Analysis of HCV SPRINT-1 (2010) (2)
Urinary monoclonal immunoglobulin in multiple myeloma. (1981) (2)
Epidemiology of delta infection in Spain. (1987) (2)
Removal from liver transplantation list of a hepatitis C virus‐HIV co‐infected patient after successful treatment with sofosbuvir and daclatasvir (2016) (2)
[Pulmonary lesions in rheumatoid arthritis]. (1976) (2)
Norfloxacin prevents spontaneous bacterial peritonitis (SBP) in cirrhosis. Final results of a multicenter double-blind placebo controled study (1990) (2)
RISK SCORE FOR HEPATOCELLULAR CARCINOMA IN CAUCASIANS WITH CHRONIC HEPATITIS B UNDER 5-YEAR ENTECAVIR OR TENOFOVIR THERAPY (2015) (2)
Nitric oxide may contribute to nocturnal hemodynamic changes in cirrhotic patients. (2000) (2)
Drugs in Development for Hepatitis B (2012) (2)
Baseline HCV‐RNA levels in genotype 1 chronic hepatitis C patients: The role of different cut‐off points (2016) (2)
Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide (2021) (2)
Interferon vs. adenine arabinoside 5′‐monophosphate in patients with anti‐HBe‐positive chronic hepatitis (1996) (2)
PIN28 USE OF PEGINTERFERON ALFA-2B IN CHRONIC HEPATITIS C PATIENTS FAILING PRIOR THERAPY: A COSTEFFECTIVENESS ANALYSIS (2008) (2)
Three years of lamivudine in anti-HBe positive patients decreased virological and biochemical response (2002) (2)
[Pleuropulmonary involvement as the only manifestation of Waldenström's macroglobulinemia]. (1984) (2)
Clinical associations of anti-HCV (1991) (2)
Response-Guided Therapy With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin Reduces Treatment Duration in NaïVE and Peginterferon Alfa-2B/Ribavirin Previous-Treatment-Failure Patients With HCV Genotype 1 (2011) (2)
T2-weighted signal hyperintensity along the corticospinal tract: a new sign of brain involvement in cirrhosis (2001) (2)
Screening and treatment of hepatitis C virus infection of adult general population in Spain is cost-effective (2018) (2)
[Value of determining the serum DNA of the hepatitis B virus as a marker of viral replication]. (1986) (2)
Chronic hepatitis D in intravenous drug addicts and non-addicts. A comparative clinico-pathological study. (1988) (2)
[One year treatment with lamivudine in different hepatitis B virus related hepatic diseases]. (1999) (2)
Repeated transmission of HCV from surgeon to patients during cardiac surgery (1995) (2)
Therapy with direct-acting antivirals for genotype 3 patients: interferon's last gasp? (2015) (2)
Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B (2021) (2)
[Intrafamilial diffusion of the hepatitis B virus. A study of familial contacts of chronic carriers]. (1986) (2)
[Hepatocarcinoma and killer cell activity]. (1995) (2)
609 A SIMPLE DIAGNOSTIC STRATEGY BASED ON ROUTINE CLINICAL DATA AND TRANSIENT ELASTOGRAPHY ACCURATELY DETECTS EARLY PORTAL HYPERTENSION IN PATIENTS WITH ASYMPTOMATIC LIVER DISEASE (2012) (2)
Diagnostic usefulness of anti-HBc-IgM and anti-HD antibodies in acute viral hepatitis. (1986) (2)
Naïve hepatitis B e antigen-negative chronic hepatitis B patients are at risk of carotid atherosclerosis: A prospective study (2021) (2)
1108 ULTRA-DEEP-PYROSEQUENCING OF PRECORE REGION OF HEPATITIS B VIRUS (2011) (2)
485 The improved therapeutic effects of adefovir dipivoxil in patients with HBeAg-negative chronic hepatitis B offset against its increased cost compared to lamivudine (2006) (1)
Management of hepatitis B in 2009 (2009) (1)
Decompensated Liver Disease due to Primary Hepatic Amyloidosis: Is Liver Transplantation Still Mandatory? (2019) (1)
Chronic Hepatitis B is Associated with Increased Cardiovascular Risk Assessed by Intima-Media Thickness (2016) (1)
P0555 : Insertions and/or deletions in the main regulatory region of hepatitis B virus suggest multicoding of the X protein (2015) (1)
IDDF2019-ABS-0134 Sofosbuvir/velpatasvir is effective and safe in patients with concomitant proton pump inhibitor use in clinical studies (2019) (1)
Prevention of HBV recurrence after liver transplant: The role of combination therapy (2009) (1)
Sclerosing Cholangitis Related to IgG4: Not Always a Curable Entity. (2018) (1)
[Interferon treatment of chronic viral hepatitis in Catalonia, Spain. Retrospective analysis]. (1999) (1)
Cross-sectional evaluation of circulating hepatitis B virus RNA and DNA: Different quasispecies? (2021) (1)
Hepatitis C Virus(HCV)Circulates as a Population ofDifferent butClosely Related Genomes:Quasispecies Nature ofHCV GenomeDistribution (1992) (1)
LINK-B: study protocol of a retrospective and prospective project for identification and linkage to care of people living with hepatitis B in a large health area of Barcelona (2022) (1)
Two doses of PEG-interferon alfa-2b plus rivabirin in genotype 1 naive patients with chronic hepatitis (2002) (1)
Does twice‐weekly administration of peginterferon alfa‐2b really improve viral kinetics in patients with chronic hepatitis C genotype 1? (2004) (1)
Transplantation of livers from donors positive for antibody to hepatitis B core antigen: transmission of hepatitis B infection and clinical course (2001) (1)
Hepatitis C virus dynamics during induction with high PEG-IFN doses and ribavirin compared with low PEG-IFN doses plus ribavirin in naive patients with chronic hepatitis C, genotype 1 (2001) (1)
418 UTILITY OF HISTORICAL DATA COMPARED TO LEAD-IN RESPONSE IN PREDICTING SUSTAINED VIROLOGIC RESPONSE IN NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR+PEGINTERFERON ALFA-2B/RIBAVIRIN (P/R) (2011) (1)
[Quantitative determination of HBV-DNA in chronic hepatitis B: comparison of three methods]. (1998) (1)
Screening and treatment difficulties of hepatitis C virus infected patients with substance use disorders or dual pathology, despite centralized management in an addiction and dual diagnosis center (2020) (1)
Nonradiactive labelling of HBV-DNA from human serum by P.C.R. (1991) (1)
Dicoxygenin labeled DNA-probe: A new rapid nonradioactive method for hepatitis B virus DNA detection in serum (1989) (1)
448 RESPONSE-GUIDED THERAPY WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN REDUCES DURATION IN NAIVE AND PEGINTERFERON ALFA-2B/RIBAVIRIN PREVIOUS-TREATMENT-FAILURE PATIENTS WITH HCV GENOTYPE 1 (2011) (1)
Second generation HCV EIA evaluation of acute PT-NANBH (1991) (1)
Hepatitis B immunoprophylaxis of low-birth-weight infants. (1985) (1)
Correction for Quer at al., High-Resolution Hepatitis C Virus Subtyping Using NS5B Deep Sequencing and Phylogeny, an Alternative to Current Methods (2016) (1)
Letter to the EditorAdefovir for lamivudine resistant HBV: More than meets the eye – Reply (2007) (1)
Securing wider EU commitment to the elimination of hepatitis C virus (2022) (1)
[Prevalence and incidence of hepatitis A in patients with hepatitis B and C]. (2000) (1)
[Prostatic vasculitis, an unusual beginning for panarteritis nodosa]. (1984) (1)
Applicability of real‐time PCR combined with melting curve analysis for the study of hepatitis B virus genome mutations (2003) (1)
[Diagnosis of acute hepatitis caused by herpes simplex virus using in situ hybridization]. (1990) (1)
Joan Cordoba Cordona (1964-2014): a dedicated clinician, great scientist, mentor, friend, collaborator, critic... (2014) (1)
1257 IS LIVER CIRRHOSIS ASSOCIATED WITH INCREASED SUSCEPTIBILITY TO INFECTION BY HEPATITIS E VIRUS (2011) (1)
[Non-A non-B hepatitis]. (1983) (1)
High-resolution Hepatitis C virus (HCV) subtyping, using NS5B deep sequencing and 3 (2014) (1)
[Enzyme-immunoassay (EIA) in the screening of hepatitis B antigen (HBsAg) in blood donors (author's transl)]. (1978) (1)
Efficacy of Boceprevir / Peginterferon / Ribavirin for HCV G 1 Compensated Cirrhotics : Meta-Analysis of 5 Trials (2014) (1)
Detection of HDV-RNA in human liver tissue by non-radioactive in situ hybridization (1990) (1)
Clinical impact and cost-effectiveness of hepatitis C testing in an emergency department in Barcelona, Spain (2022) (1)
Which is the most cost-effective combination therapy strategy for naïve patients with chronic hepatitis C? (2001) (1)
[Hepatitis A. An eradicable disease?]. (1992) (1)
646 EMBOLIZATION OF LARGE PORTAL-SYSTEMIC SHUNTS IS SAFE AND EFFECTIVE IN CHRONIC HEPATIC ENCEPHALOPATHY WITH CHILD-PUGH ≤7 (2012) (1)
Pharmacokinetics of intramuscular and intravenous HBIG: Which implications for practice? (2009) (1)
Treatment of Chronic Hepatitis B Virus with Oral Anti-Viral Therapy. (2021) (1)
[Primary solid hepatic sarcoma. Diagnosis by cytological puncture]. (1991) (1)
[Primary liver carcinoma and markers of virus of type B hepatitis (author's transl)]. (1980) (1)
581 QUANTITATIVE LONGITUDINAL EVALUATION OF HEPATITIS DELTA VIRUS RNA AND HEPATITIS B VIRUS DNA SHOWS A DYNAMIC COMPLEX REPLICATIVE PROFILE IN CHRONIC B/D COINFECTION (2009) (1)
515 Non-response and resistance to adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance (2006) (1)
[Position paper of the Catalan Society of Gastroenterology: treatment of Genotype 1 Chronic Hepatitis C Virus with Triple Therapy]. (2012) (1)
Analysis of hepatitis B virus quasispecies in circulating viral DNA and RNA: are genotype and complexity different? (2020) (0)
Cerebral magnetic resonance imaging (MRI) in patients with liver cirrhosis (1991) (0)
FRI-054-Immune-related hepatitis as an independent entity from autoimmune hepatitis: clinical, prognostic and therapeutic differences (2019) (0)
[Progressive muscular dystrophy, intra-auricular block with allopurinol]. (1984) (0)
Anti-HDV reflex testing increases the number of hepatitis D cases diagnosed in both academic and community centers (2022) (0)
[Predictive factors of response to interferon-alpha treatment in chronic hepatitis C]. (1997) (0)
Reply to: "The importance of prognostic factors in cirrhosis". (2014) (0)
Barriers to linkage to care in hepatitis C patients with substance use disorders and dual diagnoses, despite centralized management (2021) (0)
602 HEMODYNAMIC EFFECTS OF A COMBINED ACUTE TREATMENT WITH A NON-SELECTIVE BETA BLOCKER PLUS DROXIDOPA IN CIRRHOTIC RATS (2013) (0)
Assessing elderly incontinent patients. (1981) (0)
HDV-mediated inhibition of HBV in superinfection mouse model: the role of type I Interferon (2022) (0)
791 VIROLOGIC RESPONSE RATES ARE SIMILAR IN PREVIOUSLY UNTREATED AND PREVIOUSLY TREATED AND RELAPSED PATIENTS RECEIVING BOCEPREVIR TRIPLE THERAPY: A RETROSPECTIVE ANALYSIS (2013) (0)
LINK-B: a hepatitis B program to test and link to care patients lost of follow-up (2022) (0)
[Duration of the immunoprophylaxis produced by hepatitis B vaccine]. (1985) (0)
[Advances in hepatitis in 1984]. (1984) (0)
[In memorian of Sheila Sherlock]. (2002) (0)
Evaluation of anti-HCV positive donors identified during routine screening (1990) (0)
Reply: (2010) (0)
Su1064 Early Viral Kinetics Do Not Predict Treatment Outcome With Sofosbuvir + Ribavirin for 12 or 24 Weeks in HCV Genotype 2/3 Patients in the Valence Trial (2014) (0)
mTOR inhibitors a potential predisposing factor for chronic hepatitis E: Results from the prospective collaborative CHES Study (Chronic Hepatitis E Screening in patients with immune impairment and increased transaminases levels) (2023) (0)
[In memory of Joan Córdoba]. (2014) (0)
561 EFFECT OF ANTIVIRAL TREATMENTS IN EVOLUTION OF HEPATITIS B VIRUS (HBV) CORE REGION EPITOPES (2009) (0)
Corrigendum to 'Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B' [JHEP Reports 3 (2021)]. (2022) (0)
Acute hepatitis B in adulthood: not such a benign disease (2018) (0)
Synthesis of a Non-Radioactive Hepatitis B Virus DNA Probe from Human Serum by the Polymerase Chain Reaction (1994) (0)
Valeur diagnostique des anticorps anti-mitochondries (1977) (0)
Serum glutamate dehydrogenase in alcoholic liver disease. (1981) (0)
Silent cirrhosis in hepatocellular carcinoma in Spain (1991) (0)
127 PHOSPHODIESTERASE POLYMORPHISMS MAY BE ASSOCIATED WITH BASELINE THYROID STIMULATING HORMONE (TSH) AND PEGINTERFERON TREATMENT INDUCED HYPOTHYROIDISM IN PATIENTS WITH CHRONIC HEPATITIS C (2011) (0)
FRI-201-Hepatitis B virus vaccine immunogenicity in anti-HBC+ immunocompromised patients with low anti-HBS levels: Preliminary results of the Hepbare study (2019) (0)
HGV RNA quantitative method by real time RT/PCR (1997) (0)
Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain (2022) (0)
Different IgM antihdv antibody fractions in acute and chronic delta (1990) (0)
Evaluation of dried plasma spot on the cobas(r) plasma separation card as a sample type for hepatitis B virus load quantification on the cobas(r) 6800 system (2020) (0)
Efficacy of alfa-interferon to prevent chronicity in patients with acute postransfusion non-A non-B hepatitis: A randimized, controlled trial (1989) (0)
[The extrahepatic localization of the hepatitis B virus]. (1990) (0)
800 UTILITY OF ITPA GENOTYPING TO PREDICT EARLY SEVERE ANEMIA IN CHRONIC HEPATITIS C PATIENTS RECEIVING TRIPLE THERAPY (2013) (0)
Etiology of acute hepatitis in drug addicts (1986) (0)
Hepatitis Delta Virus Evolution Rate is High in Patients with Chronic Delta Infection, but Tends to Stabilize Over Time (2016) (0)
SEROLOGICAL MARKERS FOR DELTA HEPATITIS (1987) (0)
Magnetic resonance and functional abnormalities of the cortico-spinal tract in cirrhosis suggest the participation of astrocytic edema in hepatic encephalopathy (2003) (0)
Impact of the universal access to direct-acting antivirals in the profile of hepatitis C treated patients (2020) (0)
Cost-effectiveness analysis of hepatitis C virus in the Spanish population who was born between 1956 and 1970 (2017) (0)
Hepatitis C Virus Genotype 3: Hope for Nonresponders and Patients With Cirrhosis (2014) (0)
[Cryoglobulinemia and hepatic lesion]. (1979) (0)
Relation between mutations in the basal core promoter of hepatitis B virus and precore mutations, HBV genotypes and viral replication (2001) (0)
P0624 : Acute viral hepatitis: Epidemiological change during the last 25 years in Spain (2015) (0)
[Diagnosis and treatment of idiopathic hemochromatosis]. (1987) (0)
Utility of Historical Data Compared to Lead-in Response in Predicting Sustained Virologic Response in Non-Responders and Relapsers to Peginterferon/Ribavirin When Re-Treated With Boceprevir+Peginterferon Alfa-2B/Ribavirin (PR) (2011) (0)
ACE Score Identifies HBeAg-negative Inactive Carriers at a Single-point Evaluation, Regardless of HBV Genotype (2022) (0)
PIN42 Economic- and Outcomes-Related VALUE of Sofosbuvir-Based Regimens for Chronic Hepatitis C in Spain (2020) (0)
Common Genetic Variants Do Not Associate with Ifn-Induced Neutropenia in a Genome-Wide Association Study of Chronic Hepatitis C Patients in the Ideal Study (2010) (0)
Cost‐effectiveness analysis of an active search to retrieve HCV patients lost to follow‐up (RELINK‐C strategy) and the impact of COVID‐19 (2022) (0)
The cost-effectiveness of prolonged alfa interferon for chronic hepatitis C in Spain (1998) (0)
Clinical significance of alt flares in patients with chronic hepatitis B treated with lamivudine (2002) (0)
study Of Bottlenecking Transmission Of Hcv During Sexually-transmitted Acute Resolving Infection Using Ultra-deep Pyrosequencing (udps)454/roche Platform : 1033 (2010) (0)
[Diagnostic value of anti-mitochondria antibodies]. (1977) (0)
Sclerosing Cholangitis Related to IgG4: Not Always a Curable Entity (2018) (0)
HAAb TITRES IN HEPATITIS A (1979) (0)
[Gout, chondrocalcinosis and hypothyroidism]. (1984) (0)
[Antitissue antibodies not organspecific in hepatopathies]. (1977) (0)
628 PRESENCE OF HEPATITIS B VIRUS BASIC CORE PROMOTER MUTATIONS BEFORE HBEAG LOSS MAY IDENTIFY PATIENTS REQUIRING LONG TERM-TREATMENT AFTER SEROCONVERSION (2010) (0)
[Sporadic hepatitis in our milieu. Etiologic and epidemiologic study]. (1984) (0)
The Screening Guidelines for Hepatitis C Virus Infection as a milestone in the path towards hepatitis C virus elimination. (2021) (0)
Alcoholic cirrhosis and HCV infection survival of anti-HCV positive patients (1991) (0)
Chronic HCV infection : public health threat and emerging consensus held in Vienna, Austria (1996) (0)
Somatostatin plus isosorbide-5-mononitrate vs somatostatin in the control of acute gastro-esophageal variceal bleeding: A randomized controlled trial (1998) (0)
DynamicBehavior ofHepatitis C VirusQuasispecies inPatients Undergoing Orthotopic Liver Transplantation (1994) (0)
Quantitative HBV-DNA testing as an early predictor of the maintenance of response during lamivudine therapy in patients with chronic hepatitis B (2001) (0)
[E-system in acute hepatitis B type]. (1978) (0)
[HBsAg-negative post-transfusion hepatitis (author's transl)]. (1979) (0)
[Interdisciplinary collaboration in cystinosis diagnosis and monitoring therapy]. (2007) (0)
Prospective, randomized and controlled study of efficacy of surrogate marker testing for preventing NANB postransfusion hepatitis (1989) (0)
P651 CIRRHOSIS AND LIVER TRANSPLANTATION ARE ASSOCIATED WITH A HIGHER PREVALENCE OF HEPATITIS E VIRUS INFECTION (2014) (0)
[A study of 158 cases of acute delta hepatitis]. (1990) (0)
Different IgM antiVHD antibodies fractions in acute and chronic delta hepatitis (1989) (0)
Early detection and monitoring of variants resistant to lamivudine using inno-lipa HBV-DR in chronic hepatitis B (2002) (0)
Outcome of early vs. deferred antiviral treatment for recurrent hepatitis C in liver transplant recipients. (2014) (0)
Rituximab monotherapy in anti-HBC positive patients with multiple sclerosis or neuromyelitis optica spectrum disorders is not associated with HBV reactivation (2020) (0)
Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts. (2020) (0)
Thyroid Stimulating Hormone (TSH) and Peginterferon Treatment Induced Hypothyroidism May Be Associated With Phosphodiesterase Polymorphisms in Patients With Chronic Hepatitis C (2011) (0)
Evaluation of the clinical and economic value of sofosbuvir/ velpatasvir (SOF/VEL) in patients with chronic hepatitis C in Spain during the last 5 years (2022) (0)
181 TREATMENT WITH PEGYLATED INTERFERON AND RIBAVIRIN DURING EARLY ACUTE PHASE OF THE HEPATITIS C RECURRENCE VS LATE HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION (2012) (0)
Cost-Effectiveness Analysis of Hepatitis B Virus Screening to Prevent Hepatitis B Virus Reactivation in Patients Receiving Rituximab Based Chemotherapy for Hematologic Malignancy (2016) (0)
[Value of the determination of anti-HAV IgM in the diagnosis of hepatitis A]. (1984) (0)
Decreasing the Risk of HCC in Caucasian Chronic Hepatitis B Patients under NUCS: Results of the Spanish Chronic Hepatitis B Registry (Ciberhep) (2016) (0)
2nd Liver Transplantation, HBV and HCV Interdisciplinary Conference (2011) (0)
Usefulness of dried plasma spots using a plasma separation card for serological diagnosis of chronic hepatitis B and C and reflex viral load testing (2020) (0)
[IgM antibodies against hepatitis B core antigens, anti-HBc-IgM. Their diagnostic significance]. (1984) (0)
[The hepatopathy of antimitochondria antibodies. Criteria for its differentiation from primary biliary cirrhosis]. (1977) (0)
Study of HBV and HDV replication in HBsAg positive fulminant hepatitis (1989) (0)
[Economic evaluation of combined therapy in chronic hepatitis C]. (2000) (0)
PIN39 - IS THE UNIVERSAL POPULATION HEPATITIS C VIRUS SCREENING A COST-EFFECTIVE STRATEGY? A SYSTEMATIC REVIEW OF THE ECONOMIC EVIDENCE (2018) (0)
Anti-HCV detected by second generation EIA in patients with hepatocellular carcinoma (1991) (0)
Chronic hepatitis delta with normal ALT and hepatitis D viremia (2022) (0)
Projecting the Long-Term Clinical Impact of Boceprevir in Patients With Chronic Hepatitis C Genotype-1 Who Failed Prior Treatment With Peginterferon/Ribavirin (2011) (0)
[Gallbladder empyema caused by Salmonella enteritidis]. (1988) (0)
[Vaccination against hepatitis B in a hematology-hemotherapy service: analysis of its immunogenous capacity]. (1984) (0)
FRI-197-Prediction of elastographic reversion of cirrhosis after 5 years of entecavir or tenofovir disoproxil fumarate therapy in caucasian chronic hepatitis B patients (2019) (0)
[Demyelinating polyneuropathy associated with Waldenstromś macroglobulinemia with anti-myelin antibodies]. (1986) (0)
Hepatitis B virus quasispecies complexity is lower in hepatitis B virus–hepatitis D virus infection than in hepatitis B virus monoinfection (2017) (0)
1324 QUASISPECIES HOMOGENIZATION AND IL-28 GENOTYPE (RS12979860 AND RS8099917) MAY FAVOUR SELF-RESOLVING INFECTION AFTER HCV BOTTLENECKING TRANSMISSION (2011) (0)
Hepatitis B virus (HBV) DNA quantification and HBV genotypes detection in dried blood specimens (2003) (0)
613 ULTRA-DEEP PYROSEQUENCING AS A TOOL FOR THE ANALYSIS OF HEPATITIS B VIRUS QUASISPECIES EVOLUTION: STUDY OF A PATIENT SEQUENTIALLY TREATED WITH NUCLEOSIDE AND NUCLEOTIDE ANALOGUES (2010) (0)
Dame Sheila Sherlock (1991) (0)
Role of hepatitis B, hepatitis C and hepatitis delta virus in dual and triple chronic hepatitis coinfection (2001) (0)
HBsAg Levels Need HBV Genotyping to Differentiate Inactive Carriers HBsAg Carriers from HBeAg Negative Chronic Hepatitis B (2016) (0)
Sofosbuvir/Velpatasvir/Voxilaprevir for Previously DAAtreated Patients with Chronic Hepatitis C? (2020) (0)
Liver Involvement in Systemic Infection (1992) (0)
Relevance of a full-length genomic RNA standard and thermal shock step for 1 optimal hepatitis delta virus quantification 2 3 Running title : Thermal shock step for HDV quantification (2014) (0)
[Long term follow-up of non-symptomatic HBsAg carriers]. (1991) (0)
Real clinical experience after one year of treatment with tolvaptan in patients with autosomal dominant polycystic kidney disease (2022) (0)
[Infection by delta agent in drug addicts]. (1985) (0)
Genetic variability of the hepatitis C virus. Sequence analysis of the NS3 and 5'UTR (1991) (0)
[Acalculous cholecystitis and drug addiction]. (1985) (0)
[Burkitt's lymphoma in a patient, a parenteral drug addict, with acquired immunodeficiency syndrome]. (1988) (0)
574 ALTERED NEUROMODULATOR EXPRESION WITHIN THE SUPERIOR MESENTERIC GANGLIA MAY CAUSE SYMPATHETIC ATROPHY IN PORTAL HYPERTENSIVE RATS (2012) (0)
[Acute alcoholic hepatitis and steatosis. Comparative study]. (1979) (0)
Quantification of Hepatitis B Core-Related Antigen is More Useful than Quantitative HBSAG for Identification of Inactive HBSAG Carriers (2016) (0)
The lack of improvement in liver stiffness after SVR in HCV compensated advanced chronic liver disease is associated with the risk of presenting liver related events (2018) (0)
Lack of HIV transmission after hepatitis B immunoprophylaxis (2005) (0)
An electronic alert system increases screening for hepatitis B and C and improves management of patients with haematological disorders (2020) (0)
Amplification of HDV cDNA derived from human and woodchuck liver by polimerase chain reaction (1990) (0)
[Monoclonal gammapathy without association with myeloproliferative disease]. (1979) (0)
213 Cirrhotic cardiomyopathy is reversible after liver transplantation (2004) (0)
[The delta antigenic system]. (1983) (0)
[Treatment of viral hepatitis]. (2001) (0)
New Nucleoside Analogs for the Treatment of Chronic Hepatitis B (2004) (0)
[The antigenic e system in carriers of the surface antigen of viral hepatitis B (author's transl)]. (1979) (0)
Hereditary haemochromatosis: Rapid screening of the Cys282Tyr and His63asp mutations (2000) (0)
[Placental transmission of antibodies against the hepatitis B virus]. (1982) (0)
[HTLV III infection and study of lymphocyte populations in 184 hemophiliacs]. (1987) (0)
Post liver transplant (LTx) acute HCV hepatitis and development of late complications (1998) (0)
[Prevention of post-transfusional hepatitis]. (1994) (0)
[Significance of the antigen and the anti-e antibody in patients with surface antigen of hepatitis B virus]. (1977) (0)
422 Efficacy and safety of adefovir for the treatment of patients with chronic hepatitis B (CHB) resistant to lamivudine in Spain (2004) (0)
SAT-212-Treatment with mTOR inhibitors is an independent risk factor for chronic hepatitis E in transplant patients with increased transaminases levels (2019) (0)
ABC of alcohol. (1982) (0)
PAGE-B score is simpler and has similar predictive performance with the new Asian hepatocellular carcinoma risk scores in Caucasian chronic hepatitis B patients treated with long-term entecavir or tenofovir disoproxil fumarate therapy (2020) (0)
Correction: Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study (2018) (0)
Standardized Hepatitis B Virus RNA Quantification in Untreated and Treated Chronic Patients: a Promising Marker of Infection Follow-Up (2022) (0)
2015 GENOME WIDE ANALYSIS OF PATIENTS FROM THE IDEAL STUDY IDENTIFIES A CAUSAL ROLE FOR ITPA GENETIC VARIATION IN RIBAVIRIN-INDUCED HEMOLYTIC ANEMIA (2010) (0)
PMU80 DETERMINING THE EPIDEMIOLOGY, PATIENT FLOW, TREATMENT AND UNMET NEEDS OF PATIENTS WITH CHRONIC LIVER DISEASE-ASSOCIATED SEVERE THROMBOCYTOPENIA UNDERGOING INVASIVE PROCEDURES IN SPAIN (2019) (0)
[Hepatic encephalopathy in a 57-year-old male with Caroli's disease]. (1987) (0)
[Active immunization against hepatitis B]. (1982) (0)
462 DOES HBV-DNA LEVEL PRIOR LIVER TRANSPLANTATION INFLUENCE HBV RECURRENCE AND SURVIVAL OF LTX PATIENTS UNDER HBIG AND ORAL ANTIVIRALS? (2010) (0)
Pulmonary tuberculosis and fiberbronchoscopy (1984) (0)
Sofosbuvir/ledipasvir plus ribavirin achieves high SVR12 in genotype‐3 patients with compensated cirrhosis and similar to sofosbuvir plus daclatasvir: a multicentre real life cohort (2016) (0)
A new pronostic model for short-term survival in cirrhosis. Comparison with the pugh-child classification (1989) (0)
[How and whom to vaccinate against hepatitis B in Spain]. (1984) (0)
379 ULTRA-DEEP PYROSEQUENCING OF BASIC CORE PROMOTER, PRECORE AND CORE REGIONS OF HEPATITIS B VIRUS TO STUDY VIRAL VARIABILITY AND QUASISPECIES COMPLEXITY (2013) (0)
Detection of hepatitis B virus DNA in serum by PCR after antiviral therapy in patients with chronic hepatitis B (1991) (0)
HYPERTENSION IN HAEMODIALYSIS PATIENTS: STUDY OF PREVALENCE: PP.8.205 (2011) (0)
Poor outcome of acute hepatitis E in liver cirrhosis and transplant recipients (2018) (0)
[Determination of the DNA of hepatitis B virus. A new marker?]. (1986) (0)
Delta agent in nondrug addicts (1985) (0)
[Systemic embolism in hyperthyroidism]. (1979) (0)
P1130 FUTILITY TESTING AT TREATMENT WEEK 8 IN PATIENTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE 1 INFECTION RECEIVING BOCEPREVIR: A POST HOC ANALYSIS (2014) (0)
[Serologic and hepatic correlation of the markers of hepatitis B and D virus]. (1986) (0)
[Risk of transmission of HIV or hepatitis B or C viruses from an infected physician. Preventive measures]. (2007) (0)
[System e in acute hepatitis B]. (1978) (0)
[Has the hepatitis C virus been discovered?]. (1990) (0)
648 CHANGING PATTERN OF HEPATITIS DELTA VIURS INFECTION IN THE NORTHEAST OF SPAIN (CATALONIA) DURING THE LAST 25 YEARS (2008) (0)
Managing Patients on Interferon (1996) (0)
An algorythm including quantitave HBsAg and HBcrAg is useful for discrimation between hepatitis B virus inactive carriers and patients with active chronic hepatitis B HBeAg negative (2017) (0)
PG112 MODELING THE LONG-TERM COST-EFFECTIVENESS OF CRONIC HEP. B THERAPIES IN SPAIN (2008) (0)
[Clinical characteristics of chronic autoimmune hepatitis. Study of 51 cases]. (1989) (0)
Viral load at 15 days after liver transplantation as a good predictor of fast liver fibrosis progression (2017) (0)
[Presence of anti-HBc antibodies in Australia-antigen-negative hepatitis]. (1979) (0)
[Morphologic changes of alcoholic hepatitis after alcohol abstinence. Multivariate factorial analysis]. (1986) (0)
Rethinking the inactive carrier state: management of patients with low‐replicative HBeAg‐negative chronic hepatitis B and normal liver enzymes (2020) (0)
P1110 HIGH-RESOLUTION HCV SUBTYPING USING MASSIVE SEQUENCING AND PHYLOGENY, OPTIMAL ALTERNATIVE TO CURRENT METHODS (2014) (0)
Is Peg-interferon plus ribavirin a cost-effective therapy, and if so, what is the most efficient way to use this therapy in naive patients with chronic hepatitis C? (2002) (0)
Early predictors of antiviral treatment response in liver transplant recipients with recurrent hepatitis C genotype 1 (2014) (0)
934 LONG-TERM FOLLOW-UP OF HEMODYNAMIC RESPONDERS TO PHARMACOLOGICAL THERAPY AFTER VARICEAL BLEEDING: A COHORT-STUDY (2011) (0)
distribution.quasispecies nature of HCV genome population of different but closely related Hepatitis C virus (HCV) circulates as a (2013) (0)
[Diagnosis of viral hepatitis type A by radioimmunoassay (author's transl)]. (1980) (0)
Can alpha-fetoprotein predict the recurrence and mortality of HCC patients treated by liver transplant? (1998) (0)
Gel containing F2alpha prostaglandins. Effect on ripening of the uterine cervix and the onset of labor (1979) (0)
Comparision of different non isotopic and isotopic methods for detection of HBV-DNA in serum (1990) (0)
[Adefovir dipivoxil compassionate use program in Spain: efficacy and resistance analysis]. (2007) (0)
[Acquired immunodeficiency syndrome and Hodgkinś disease]. (1986) (0)
[HTLV-III infection in risk groups]. (1986) (0)
[Histologic evolution of acute alcoholic hepatitis]. (1981) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Rafael Esteban?

Rafael Esteban is affiliated with the following schools:

Rafael Esteban's Academic­Influence.com Rankings

Rafael Esteban's Degrees

Similar Degrees You Can Earn

Why Is Rafael Esteban Influential?

Rafael Esteban's Published Works

Published Works

What Schools Are Affiliated With Rafael Esteban?

Rafael Esteban's AcademicInfluence.com Rankings